2025 MaTOS Lung | Session II | Early-Stage Resectable Lung Cancer
Overview
Dr. Scholl highlighted pathologists’ role in assessing residual tumor after neoadjuvant therapy, urging standardized methods, clear communication, and reconsidering RVT cutoffs.
Dr. Lee reviewed perioperative immunotherapy trials, noting survival gains, surgical attrition, worse outcomes without surgery, and stronger benefit in PD-L1–positive patients.
Dr. Reuss advocated perioperative immunotherapy as the 2025 standard, citing survival data and benefit for non-pCR patients, and called for definitive trials like ADOPT-Lung.
Dr. Halmos argued against perioperative immunotherapy as standard, citing limited benefit and surgical attrition, urging personalized, biomarker-driven care; the debate remained divided.
Dr. Devarakonda reviewed adjuvant therapy selection, noting chemo-IO benefits in stage II–III disease and emerging roles for TMB, RNA assays, and ctDNA.
The Q & A Session addressed neoadjuvant vs perioperative lung cancer therapy, similar pCR rates, higher Asian responses, pCR assessment challenges, AI role, and preference for neoadjuvant in stage II–III.
Dr. Lee reviewed perioperative immunotherapy trials, noting survival gains, surgical attrition, worse outcomes without surgery, and stronger benefit in PD-L1–positive patients.
Dr. Reuss advocated perioperative immunotherapy as the 2025 standard, citing survival data and benefit for non-pCR patients, and called for definitive trials like ADOPT-Lung.
Dr. Halmos argued against perioperative immunotherapy as standard, citing limited benefit and surgical attrition, urging personalized, biomarker-driven care; the debate remained divided.
Dr. Devarakonda reviewed adjuvant therapy selection, noting chemo-IO benefits in stage II–III disease and emerging roles for TMB, RNA assays, and ctDNA.
The Q & A Session addressed neoadjuvant vs perioperative lung cancer therapy, similar pCR rates, higher Asian responses, pCR assessment challenges, AI role, and preference for neoadjuvant in stage II–III.
Target Audience
Physicians
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Moderator: Karen Kelly, MD
Speakers and Panelists:
Lynette M. Sholl, MD
Jay M. Lee, MD
Joshua E. Reuss, MD
Balazs Halmos, MD
Sid Devarakonda, MD
Panelists:
Jeffrey Bradley, MD
Fred R. Hirsch, MD, PhD, FASCO
Delvys Rodriguez Abreu, MD, PhD
Date of Release
January 7th, 2026
-1769196766441.webp&w=3840&q=75)
-1769196674841.webp&w=3840&q=75)